Menovo(SH:603538) Xin Lang Cai Jing·2026-02-12 08:40Core Viewpoint - Meinuo Pharma's wholly-owned subsidiary, Meinuo TianKang, is participating in the national organized procurement for drugs, with 10 products, including Perindopril tert-butylamine tablets, expected to be selected for procurement [1] Group 1 - The total sales revenue of the 10 products is projected to be 71.75 million yuan, accounting for 6.4% of the company's revenue for the first three quarters of 2025 [1] - The number of selected products represents 40% of the total number of formulations in the company's formulation segment [1] - The results of the selection process are expected to be finalized by the end of March 2026, with the procurement cycle lasting until December 31, 2028 [1] Group 2 - There is uncertainty regarding the signing of the procurement agreement and the execution of sales [1]